JPRN-UMIN000012515尚未招募2 期
To evaluate the efficacy and safety of Erlotinib and Bevacizumab in patients with advanced Non-squamous Non-Small Cell Lung Cancer with brain metastasis who acquired resistance to prior EGFR-TKI treatment harboring EGFR mutation. - To evaluate the efficacy and safety of Erlotinib and Bevacizumab in patients with advanced Non-squamous Non-Small Cell Lung Cancer with brain metastasis who acquired resistance to prior EGFR-TKI treatment harboring EGFR mutation.
Department of Respiratory Medicine, Kumamoto University Hospital0 个研究点目标入组 16 人开始时间: 2013年12月9日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •first enrollment 1)Squamous cell carcinoma 2)brain metastasis 3)Pregnant or breast-feeding females second enrollment 1)Interstitial pneumonia or pulmonary fibrosis on chest CT scans 2)History of EGFR-TKI, VEGF antibody allergic reaction. 3)Radiotherapy enforcement example for the brain 4)Brain metastasis expected bleeding 5)Active severe comorbidity disease. 6)History of hemoptysis 7)Uncontrollable hypertension 8)History of gastrointenstinal perforation or diverticulitis or fistula 9)Scheduled operation 10)Active concomitant malignancy 11)Pregnant or breast-feeding females 12)Inappropriate patients for this study judged by the physicians
研究者
相似试验
已完成
不适用
Efficacy and pharmacokinetics study of erlotinib in patients with non-small cell lung cancerAdvanced non-small cell lung cancerJPRN-UMIN000012862Shizuoka cancer center70
已完成
不适用
Evaluation of efficacy of erlotinib in patients with untreated, EGFR mutation positive, untreated-locally advanced NSCLC.ntreated, EGFR mutation positive, untreated-locally advanced NSCLC.JPRN-UMIN000011467agasaki Thoracic Oncology Group10
已完成
1 期
Safety evaluation of coadministration of erlotinib and theracurmin in non-small cell lung cancer patientsnon-small cell lung cancerJPRN-UMIN000013424Saitama Medical Center6
进行中（未招募）
1 期
A Phase II Trial of Erlotinib as first line therapy in Non- Small Cell Lung Cancer over-expressing EGFR - Study of targeted Erlotinib treatment for Non-small cell lung cancerStage IIIb/IV non-small cell lung cancer (NSCLC) tumours that over-express EGFRMedDRA version: 9.1 Level: LLT Classification code 10025054 Term: Lung cancer non-small cell stage IIIBMedDRA version: 9.1 Level: LLT Classification code 10029522 Term: Non-small cell lung cancer stage IVEUCTR2007-001264-72-GBOxford Radcliffe Hospitals NHS Trust35
已完成
1 期
Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung CancerEGFR-Mutant Lung CancerNCT01967095Memorial Sloan Kettering Cancer Center53